• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Tailoring Diabetes Care and Gauging Physician Knowledge on Treatment Strategies for Older vs Younger Adults

Opinion
Video

Medha Munshi, MD, and Conan Tu, MD, MBA, DACD, BC-ADM, begin a discussion on geriatric diabetes care by providing an overview of the condition and gauging physician knowledge with polling questions.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
      Impact of Social Determinants of Health on Key Cardiometabolic Measures Amplified by New Research
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      Intermediate Cardiometabolic Risk: Study Author Explains this "Critical Inflection Point"
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      US Cardiometabolic Health at Alarming Suboptimal Levels, Says Lead Author of New NHANES Analysis
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      Lessons Learned from the VA on Delay in Second-line Treatment for Type 2 Diabetes
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      VA Clinical Investigator Discusses HbA1c, Comorbidities as Markers for T2D Treatment Intensification
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      DiabetesWise Pro: Side-by-side, Feature-by-feature CGM Comparison, Plus More
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      A Guide to Prescribing the Right Diabetes Device for your Patients, with DiabetesWise Pro Developer Korey Hood, PhD
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Diabetes Device Comparison Made Easy: The Story Behind DiabetesWise Pro
      Related Content
      Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin Plus CGM

      Omnipod 5 System Leads to Significant Glycemic Improvements After Direct Transition from MDI Insulin with CGM

      Grace Halsey
      March 27th 2025
      Article

      Mean reduction in HbA1c was nearly 1% after transition from MDI plus CGM to Omnipod 5 in the first randomized trial to evaluate the shift in mode of insulin delivery.

      Obesity & Type 2 Diabetes: An Expert Discussion

      Obesity & Type 2 Diabetes: An Expert Discussion

      Sydney Jennings
      June 30th 2023
      Podcast

      In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

      Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

      Cost of Semaglutide, Tirzepatide Prohibitive Despite Significant Benefits

      Grace Halsey
      March 14th 2025
      Article

      A new economic evaluation estimates that semaglutide would need to drop its current price by 81.9% and tirzepatide by 30.5% to be cost effective.

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Episode 17: Kidney Outcomes with Tirzepatide in Type 2 Diabetes

      Sydney Jennings
      July 22nd 2022
      Podcast

      "Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Hiddo Heerspink, PhD, PharmD.

      FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose / image credit: ©New Africa/AdobeStock

      FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose

      Sydney Jennings
      March 3rd 2025
      Article

      Your daily dose of the clinical news you may have missed.

      FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

      FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Diabetes

      Patient Care Editorial Staff
      February 14th 2025
      Article

      Merilog joins two long-acting insulin biosimilar products approved in 2021, bringing the total to three insulin biosimilars available in the United States.

      © 2025 MJH Life Sciences

      All rights reserved.